Prior Authorization Denied for Wegovy or Zepbound: What to Do Next
A denial letter is frustrating, but it is not the end of the road. Follow these evidence-based steps to overturn the decision or lower your out-of-pocket cost.
If your insurance company just denied prior authorization for Wegovy or Zepbound, you still have several proven options: correct clerical errors, file a medical-necessity appeal with stronger documentation, ask your prescriber to try a step-therapy exemption, or compare self-pay programs such as Rx.com’s compounded semaglutide from $99 per month and compounded tirzepatide from $149 per month. Acting quickly and following your plan’s appeal rules raises the odds of approval and prevents treatment gaps.
- Insurers deny an estimated 30–45 % of Wegovy and Zepbound prior authorization (PA) requests on the first submission, most often for missing BMI data or recent weight history.(nj.gov)
- In the 2025 AMA physician survey, 93 % of doctors said PA delays patient care and 82 % reported that denials can lead patients to abandon treatment.(ama-assn.org)
- A well-prepared appeal that includes BMI ≥30 kg/m² (or ≥27 kg/m² with a qualifying comorbidity), documented weight trends, and failed lifestyle therapy is approved about 70 % of the time.(nj.gov)
- Commercial-insurance patients may pay as little as $25 for up to 12 fills with the Wegovy or Zepbound savings card if the drug is covered; the card cannot override a PA denial.(novocare.com)
- Cash options include Rx.com’s compounded semaglutide from $99/month and compounded tirzepatide from $149/month (12-month plan, visit and shipping included).
What Prior Authorization for GLP-1 Drugs Involves
Prior authorization is the insurer’s pre-approval process that confirms a medication is medically necessary before it will be paid for. For obesity drugs like Wegovy (semaglutide 2.4 mg weekly) and Zepbound (tirzepatide up to 15 mg weekly), most U.S. plans require PA because of the high list price and ongoing supply constraints.
Typical PA forms ask for current height and weight, calculated body-mass index (BMI), a six-month weight-loss attempt with lifestyle changes, and documentation of comorbidities such as hypertension, type 2 diabetes, or obstructive sleep apnea. Medicare does not cover anti-obesity medications, but many employer and Affordable Care Act plans do, provided all criteria are met. For deeper context on how insurers set these rules, see our explainer on recent GLP-1 coverage changes.
Why Wegovy or Zepbound Gets Denied
Denials usually fall into three buckets: administrative errors, clinical criteria not met, or formulary restrictions. Understanding which one applies lets you tailor the fix.
Clerical mistakes: Missing height, weight, or ICD-10 codes (E66.9 for obesity) trigger an automatic rejection. Double-check every field on the PA form.
Criteria not met: Most plans require BMI ≥ 30 kg/m², or ≥ 27 kg/m² with at least one weight-related condition. If your BMI has dipped below the cutoff after initial weight loss, ask your prescriber to document your highest recent BMI.
Step therapy failure: Some insurers want evidence you tried cheaper agents like Saxenda (liraglutide) or generic phentermine before a GLP-1. Your doctor can request a step-therapy exemption if those drugs are contraindicated or previously ineffective.
| Common PA Criteria | Typical Plan Requirement | Documentation Needed |
|---|---|---|
| BMI threshold | ≥ 30 kg/m² or ≥ 27 kg/m² + comorbidity | Recent vitals, problem list |
| Lifestyle-therapy period | ≥ 6 months | Dietitian notes, exercise logs |
| Recent HbA1c (if diabetic) | > 6.5 % | Lab report within 90 days |
| Drug interactions review | No severe contraindications | Current med list |
| Prescriber specialty | Family, internal, or endocrinology | NPI on form |
How to Build a Winning Appeal
Most insurers allow at least one internal appeal and one external (state) review, and success rates climb when you pair medical evidence with the plan’s own policy language.
Step 1: Get the denial code and rationale. The letter cites a code such as “B56 – criteria not met.” Search the insurer’s policy bulletin to see exactly what they expect.
Step 2: Gather stronger documentation. Include:
- Six-month weight trend: EHR printout showing date-stamped weights.
- Comorbidity evidence: Sleep-study report, hypertension logs, or HbA1c lab.
- Treatment attempts: Notes on prior use or intolerance of phentermine/topiramate.
- Peer-reviewed support: Attach the 2021 STEP 1 trial (semaglutide showed 14.9 % mean weight loss).(novocare.com)
Step 3: Write a compelling cover letter. Your prescriber should cite the plan policy by name, note how each criterion is satisfied, and state that untreated obesity increases long-term cardiovascular risk.
Step 4: Submit within the deadline. Most plans allow 180 days, but acting within 30 days keeps momentum.
Step 5: Request expedited review if clinically urgent. If the patient has uncontrolled diabetes or upcoming bariatric surgery is being considered, plans must reply within 72 hours under federal rules.
Lower-Cost Options if Insurance Refuses
You have three main paths: manufacturer programs, cash-pay at retail, or compounded GLP-1 therapy.
1. Manufacturer savings cards (only if the drug is covered): Wegovy and Zepbound offer commercial copay cards that reduce the monthly cost to as low as $25 per fill for up to 12 fills, expiring 12/31/2026.(novocare.com) These cards cannot be used if the plan flat-out denies coverage or if you have Medicare or Medicaid.
2. Retail cash price: If you pay cash at a local pharmacy, list prices average $1,349 for a Wegovy 4-pen carton and $1,059–$1,315 for Zepbound depending on dose. Compare prices first by using Rx.com’s free discount card.
| Cash-Pay Option | Typical Monthly Price (Oct 2026) | Notes |
|---|---|---|
| Retail Wegovy 2.4 mg | $1,349 | Price sourced from Novo Nordisk list price 2026 |
| Retail Zepbound 10 mg | $1,315 | Eli Lilly list price 2026 |
| Rx.com compounded semaglutide | $99 | 12-month plan, any dose, visit + shipping included |
| Rx.com compounded tirzepatide | $149 | 12-month plan, any dose, visit + shipping included |
3. Compounded GLP-1 therapy: U.S. 503A pharmacies may compound semaglutide and tirzepatide when a prescriber determines an individual patient needs a change from the commercial product. The medications are not FDA-approved. For more on costs and safety, read our 2026 GLP-1 price table and our safety guide.
Should you appeal again or switch to a cash-pay option?
Check the column that fits your situation:
✅ Appeal makes sense
- BMI and comorbidities fully meet plan criteria
- Denial reason was clerical or missing document
- You have time (30–45 days) before next refill is due
- Commercial insurance would drop copay to ≤ $50 once approved
🏥 Consider cash-pay
- Plan excludes anti-obesity drugs outright
- You have Medicare, Medicaid, or a high-deductible plan with no GLP-1 coverage
- Previous appeal already denied after external review
- Medical urgency: rapid weight regain impacting diabetes control
🚨 When to Contact Your Healthcare Provider
Contact your doctor immediately if you experience any of the following:
- Severe nausea or vomiting - may signal pancreatitis, which requires prompt evaluation.
- Persistent abdominal pain - could indicate gallbladder disease linked to rapid weight loss.
- Signs of dehydration - dizziness, low blood pressure, or dark urine after stopping a GLP-1 abruptly.
- Uncontrolled blood sugar spikes - especially in patients with type 2 diabetes discontinuing therapy.
- Thoughts of self-harm or depression - call or text the 988 Suicide & Crisis Lifeline.
- Allergic reaction - swelling of face or throat after any injection.
- Severe injection-site rash - could be infection requiring antibiotics.
- Rapid weight regain > 10 lb in a month - may need urgent metabolic evaluation.
Scientific References
- Wilding JPH et al. Semaglutide 2.4 mg once weekly for weight management in adults with obesity. N Engl J Med, 2021.
- American Medical Association. 2025 AMA Prior Authorization Physician Survey Highlights, 2026.
- American Medical Association. Prior authorization delays linked to care abandonment, 2025.
- Novo Nordisk. Wegovy Savings Offer Terms and Conditions, updated April 2026.
- Eli Lilly. Zepbound Self-Pay Savings Card Program Terms, accessed October 2026.
- New Jersey Drug Utilization Review Board. Prior authorization outcomes Q1 2024, Wegovy protocol, 2024.
Frequently Asked Questions
How long does a prior authorization appeal for Wegovy usually take?
Most commercial plans must review an internal appeal within 30 calendar days. If you request an expedited review for medical urgency, the turnaround can be as fast as 72 hours. Check your denial letter for exact deadlines.
Can the Wegovy or Zepbound savings card override a denial?
No. Copay cards only lower your cost after the prescription is approved and adjudicated by insurance. They cannot bypass an outright plan exclusion or failed prior authorization.
Will switching to Ozempic or Mounjaro help with approval?
Not usually. Because Ozempic and Mounjaro are FDA-approved for diabetes, many plans cover them only if you have type 2 diabetes. Using them off-label for weight loss could violate plan rules and may still require prior authorization.
Does Medicare cover Wegovy or Zepbound in 2026?
Original Medicare and Medicare Part D plans do not cover anti-obesity medications as of October 2026. Several bills aim to change this, but none have passed yet.
What if my BMI is now below 30 kg/m² because I lost weight on another drug?
Your prescriber can submit your highest documented BMI in the last 12 months and explain that weight-loss maintenance still requires GLP-1 therapy. Some insurers accept this with proper documentation.
How many times can I appeal a prior authorization denial?
Most health plans allow at least one internal appeal and one external review through an independent medical reviewer. State Medicaid programs may have additional levels.
Are compounded semaglutide or tirzepatide the same as brand drugs?
No. Compounded formulations are not FDA-approved, and potency can vary. However, they contain the same active molecule and can be prescribed when a licensed provider determines you need a change from the commercial product.
